Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19... see more

TSXV:VXL - Post Discussion

Vaxil Bio Ltd > Corvax still a long ways away...
View:
Post by Freebirds on Jun 12, 2020 2:02pm

Corvax still a long ways away...

"Vaxil is advancing its CorVax™ preclinical program to validate effective immune response, including assessing convalescent patient plasma, in vitro cytotoxicity, in vivo immunogenicity and ex vivo T cell proliferation and cytokine release.  We anticipate completing this work in the coming months and if successful, we will prepare for and commence our Phase 1 program once receiving approval to do so.

If we are successful in proving the safety of our COVID-19 Vaccine in Phase 1, we will continue the development of CorVax™ to Phase 2 and 3. Vaxil’s signal peptide platform is more easily and more efficiently scaled up"
 

Hopefully the world has a vaccine sooner than this! IF they ever get "approval" to even begin Phase 1 a few months from now...hoping for a breakthrough like most here but they have a better chance curing cancer IMO )

Comment by Iseneschal on Jun 12, 2020 2:16pm
Come on Freebirds..............Fess up.......Are you Short or Long?
Comment by Freebirds on Jun 12, 2020 2:30pm
  aha I am long but only with 45k shares...the rest sold 20 mins ago...I have 2 bids still at .075 and .08 not sure if I'll get them but I keep them there for small support. This should see 20-30 cents again by fall IMO 
Comment by Iseneschal on Jun 12, 2020 2:40pm
Interesting....back in March u were calling this a PoS
Comment by Freebirds on Jun 12, 2020 2:58pm
  VXL is manipulated by rookie "market makers" with only a few tricks in the bag making it somewhat easy to accumulate "free shares" which is what I currrently own and the bids I have are from profits of the past few pump and dumps which is what this POS is currently only good for but at this current SP...FOMO has the best of me )  I will prob only remain long ...more  
Comment by Iseneschal on Jun 12, 2020 3:08pm
Great story
Comment by threefiftynine on Jun 12, 2020 3:09pm
so its a pos but you will remain long until it gets get eaten up by bp----gotcha
Comment by whateveryousay on Jun 12, 2020 2:20pm
I am currently on an immune drug this is the big area of study right now no cures yet but companies like Vaxil are on the cutting edge of cancer therapy a good place to park some money.Lots of drugs can kill cancer but they also kill the patient.These small bio companies often do the innovative research and are then swallowed by the evil pharma giants.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities